{"entity":{"id":"solve-therapeutics","kind":"company","name":"Solve Therapeutics","aka":[],"tldr":"Solve Therapeutics makes antibody-drug conjugates: antibodies that carry a strong cancer drug straight to tumour cells. Its two lead medicines are in early trials in people with advanced solid tumours.","summary":"Solve Therapeutics, based in San Diego, California, develops antibody-drug conjugates built on CloakLink, which the company describes as a proprietary hydrophilic linker system engineered to mask the hydrophobic properties of ADC payloads. Its two lead programmes, SLV-154 and SLV-324, target membrane receptor proteins on solid tumours that the company has not named publicly, and both are in phase 1 dose-escalation studies (NCT06771219 and NCT07108114). A third registered study, NCT07728942, uses SLR-108, an antibody-radionuclide conjugate, with the unlabelled antibody SLX-1411 for PET imaging in metastatic solid tumours. In November 2025 the company announced an oversubscribed USD 120 million financing led by Yosemite, with Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co. and SymBiosis joining existing investors including Alexandria Venture Investments, General Atlantic and Surveyor Capital. Its first registered cancer trial, NCT06771219, was posted on ClinicalTrials.gov in January 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://solvetx.com/"},{"label":"USD 120 million financing release, November 2025","url":"https://solvetx.com/news/solve-therapeutics-raises-120-million-to-develop-best-in-class-adcs-for-solid-tumors/"},{"label":"ClinicalTrials.gov: phase 1 trial of SLV-154 (NCT06771219)","url":"https://clinicaltrials.gov/study/NCT06771219"},{"label":"ClinicalTrials.gov: phase 1 trial of SLV-324 (NCT07108114)","url":"https://clinicaltrials.gov/study/NCT07108114"},{"label":"ClinicalTrials.gov: phase 1 PET imaging study of SLR-108 (NCT07728942)","url":"https://clinicaltrials.gov/study/NCT07728942"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website or in the November 2025 release.","The antigens targeted by SLV-154 and SLV-324 are not disclosed on the company website.","Company website, financing release and ClinicalTrials.gov records read on 29 October 2026."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://solvetx.com/","stage":"growth","investors":["alexandria-venture-investments"],"funding":[{"round":"Financing (round not named)","year":2025,"amountUsd":120000000,"source":"https://solvetx.com/news/solve-therapeutics-raises-120-million-to-develop-best-in-class-adcs-for-solid-tumors/","note":"Oversubscribed and upsized; led by Yosemite. The release does not name the round."}]},"route":"/companies/solve-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"company":[{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/"},{"id":"solu-therapeutics","kind":"company","name":"Solu Therapeutics","route":"/companies/solu-therapeutics/"}]}}